Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139855 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4E | |
| SCHEMBL29687292 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4E | |
| SCHEMBL9561185 | 0.67 | MGLL (0.40) | ALDH1A1HPGDGAAHSD17B10TP53 | |
| SCHEMBL29677813 | 0.66 | ALDH1A1 (0.68) | HCAR3ALDH1A1HPGDKDM4EGAA | |
| SCHEMBL2804157 | 0.66 | ALDH1A1 (0.68) | HCAR3ALDH1A1HPGDKDM4EGAA | |
| SCHEMBL29797781 | 0.66 | MGLL (0.43) | ALDH1A1HPGDGAAHSD17B10TP53 | |
| Terephthalic Acid SCHEMBL2944670 | 0.65 | RARB (0.68) | ALDH1A1TP53TSHRPLA2G4BRARB | |
| Terephthalic Acid SCHEMBL1884274 | 0.65 | RARB (0.68) | ALDH1A1TP53TSHRPLA2G4BRARB | |
| SCHEMBL4871445 | 0.65 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL3350732 | 0.65 | DRD2 (0.59) | HCAR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | HCAR3 1122/4885ALDH1A1 957/4885HPGD 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.